Skip to main content
KZIA logo

Kazia Therapeutics Limited

KZIANASDAQHealthcareBiotechnology

$7.87Today:- (-)1Y +19.73%

As of Oct 26, 2026 close

Market cap
$24.56M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$4.86$17.40
Volume (live)
-
Avg. volume (3M)
262.99K

Kazia Therapeutics Limited (KZIA) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Kazia Therapeutics Limited stock.

Analyst Consensus Rating

Investment consensus from 5 professional research analysts

Consensus Rating

Buy
Based on 5 unique analysts
(6 total ratings in last 90 days)
Medium Confidence∞:1 Buy/Sell

Average Price Target

$30.40
+286.28% upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest KZIA Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Kambiz Yazdi
BTIG
BuyMaintains
$40.00
Paul Jeng
Guggenheim
BuyInitiates
$35.00
Andrew Berens
Leerink Partners
BuyInitiates
$30.00
Sean Lee CFA
HC Wainwright
BuyReiterates
$18.00
Kambiz Yazdi
BTIG
BuyMaintains
$40.00
John Newman
Canaccord Genuity
BuyReiterates
$29.00

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 22, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for KZIA?

The analyst consensus rating for KZIA is Buy, based on the latest ratings from 5 analysts over the last 90 days.

What is the average price target for KZIA?

The average 12-month price target for KZIA is $30.40, representing an upside of 286.3% from the Oct 26, 2026 close of $7.87.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.